Logo

The US FDA Puts Clinical Hold on Iovance Biotherapeutics’ (IOV-LUN-202) Trial of LN-145 for Non-Small Cell Lung Cancer

Share this
Iovance Biotherapeutics

The US FDA Puts Clinical Hold on Iovance Biotherapeutics’ (IOV-LUN-202) Trial of LN-145 for Non-Small Cell Lung Cancer

Shots:

  • The trial has been halted on Dec 22, 2023 due to grade 5 (fatal) SAE potentially related to the non-myeloablative lymphodepletion pre-conditioning regimen
  • The (IOV-LUN-202) study assesses LN-145 in advanced NSCLC patients who progressed after CT and anti-PD-1 therapy, without EGFR, ROS, or ALK genomic mutations and have received targeted therapy if indicated by other actionable tumor mutations and have undergone at least one line of targeted therapy
  • Furthermore, Iovance will halt enrollment and the LN-145 TIL treatment regimen for new patients while the previous treated patients with LN-145 in the trial will continue to be monitored as per the protocol. For patients who have undergone tumor resection, the LN-145 TIL treatment regimen will continue with added precautions and risk mitigations

Ref: Iovance Biotherapeutics | Image: Iovance Biotherapeutics

Related News:- Iovance Biotherapeutics Reports the First Patient Randomizing of Lifileucel in P-III Trial (TILVANCE-301) for Frontline Advanced Melanoma

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

 

Click here to­ read the full press release 

Shivani Chandra

Shivani was a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She was covering news related to Product approvals, clinical trial results, and updates. We can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions